Logo     Print Page  Close Window


SEC Filings


10-Q
FIBROCELL SCIENCE, INC. filed this Form 10-Q on 08/09/2018
Entire Document
 
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
Note 5. Warrants (continued)

In March 2017, the Company issued warrants to purchase 687,468 shares of its common stock in connection with the Company’s public offering of convertible preferred stock and warrants (each a Series A Warrant and collectively, the Series A Warrants), more fully described in Note 10. Each Series A Warrant has an exercise price of $12.69, is exercisable six months after the date of issuance and will expire five years from the date of issuance.

The Company’s outstanding warrants consist of both liability-classified warrants and equity-classified warrants. The following table summarizes outstanding warrants to purchase the Company’s common stock:
 
Number of warrants
 
 
 
 
 
June 30, 2018
 
December 31, 2017
 
Exercise
Price
 
Expiration
Dates
Liability-classified Warrants
 
 
 
 
 
 
 
Issued with June 2012 Convertible Notes

 
75,040

 
$
37.50

 
Jun 2018
Issued in Series E Preferred Stock offering
104,676

 
104,676

 
$
112.50

 
Dec 2018
Issued with September 2016 Convertible Notes
1,205,840

 
1,205,840

 
$
22.50

 
Sep 2021
Total liability-classified warrants
1,310,516

 
1,385,556

 
 
 
 
 
 
 
 
 
 
 
 
Equity-classified Warrants
 
 
 
 
 
 
 
   Issued in 2017 Series A Preferred Stock Offering
687,468

 
687,468

 
$
12.69

 
Mar 2022
Issued in December 2017 Offering - common warrants
2,679,702

 
2,809,404

 
$
3.85

 
Dec 2022
Issued in December 2017 Offering - underwriter warrants
87,274

 
87,274

 
$
4.8125

 
Dec 2022
Issued in December 2017 Offering - pre-funded warrants

 
483,221

 
$
0.05

 
No exp
Issued in May 2018 Private Placement - common warrants
1,528,668

 

 
$
2.86

 
Nov 2023
Issued in May 2018 - underwriter warrants
142,676

 

 
$
3.679

 
May 2023
Total equity-classified warrants
5,125,788

 
4,067,367

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total outstanding warrants
6,436,304

 
5,452,923

 
 

 
 

The table below is a summary of the Company’s warrant activity during the six months ended June 30, 2018:
 
Number of warrants
 
Weighted-
average
exercise
price
 
Liability-classified
Equity-classified
Total
 
Outstanding at December 31, 2017
1,385,556

4,067,367

5,452,923

 
$
11.32

Granted

1,671,344

1,671,344

 
2.93

Exercised

(612,923
)
(612,923
)
 
0.85

Expired
(75,040
)

(75,040
)
 
37.50

Outstanding at June 30, 2018
1,310,516

5,125,788

6,436,304

 
$
9.83



17